|
Security
Type
|
Security Class
Title
|
Fee
Calculation
Rule
|
Amount
Registered(1)
|
Proposed
Maximum
Offering
Price Per
Unit(2)
|
Maximum
Aggregate
Offering Price
|
Fee Rate
|
Amount of
Registration
Fee
|
|
Equity
|
Common Stock, $0.001 par value per share, BridgeBio Pharma, Inc. Amended and Restated 2019 Inducement Equity Plan
|
Rule 457(c) and Rule 457(h)
|
1,750,000(3)
|
$40.20
|
$70,350,000.00
|
$0.00014760
|
$10,383.66
|
|
Total Offering Amounts
|
$70,350,000.00
|
—
|
|||||
|
Total Fee Offsets
|
—
|
||||||
|
Net Fee Due
|
$10,383.66
|
||||||
| (1) | Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall also cover any additional shares of common stock which become issuable under the above-named plans by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of our outstanding shares of common stock. |
| (2) |
Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457 of the Securities Act, and based on the average of the high and low sales
prices of the registrant’s common stock, as quoted on the Nasdaq Global Select Market on January 2, 2024.
|
| (3) |
Represents 1,750,000 additional shares of common stock that were added to the shares reserved and available for issuance under the BridgeBio Pharma, Inc. Amended and Restated 2019
Inducement Equity Plan (formerly known as the BridgeBio Pharma, Inc. 2019 Inducement Equity Plan), as approved by the Board of Directors of the registrant,
effective on December 13, 2023.
|